GENE SERPINA1: POTENCIAL MARCADOR DIAGNÓSTICO EM CARCINOMAS PAPILÍFEROS DA TIREOIDE
DOI:
https://doi.org/10.18066/revistaunivap.v27i56.2578
Resumo
As neoplasias tireoidianas são o principal tipo de malignidade endócrina, sendo atualmente consideradas um problema de saúde pública com aumento constante em sua incidência nos últimos anos. A descoberta de marcadores moleculares que possam ser aplicados na rotina clínica em conjunto com a biópsia por aspiração com agulha fina (PAAF) pode propiciar um diagnóstico mais preciso e consequentemente um tratamento mais eficiente para o paciente. O objetivo desse estudo foi avaliar se o gene SERPINA1 pode ser considerado um marcador diagnóstico em carcinomas de tireoide. Foi realizada a análise de expressão gênica pela RT-qPCR, em 32 amostras de tecido tireoidiano, sendo 13 bócios, 11 carcinomas papilíferos, quatro carcinomas foliculares e quatro tecidos não tumorais de tireoide. A expressão aumentada do gene SERPINA1 foi observada nas amostras de carcinoma papilífero em comparação com amostras de bócio (P=0.0319) e com as amostras de carcinoma folicular (P=0.0430). Não foi observada expressão diferencial significativa entre amostras de carcinoma folicular com as amostras de bócio (P= 0.5329). Os resultados da análise de expressão gênica sugerem que o gene SERPINA1 pode ser considerado um marcador diagnóstico em carcinomas papilíferos de tireoide.
Downloads
Não há dados estatísticos.
Referências
ABDULLAH, M et al. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. Peer Journal, v. 4, p. e2450, 2016.
BLANSFIELD, J. A.; SACK, M. J.; KUKORA, J. S. Recent experience with preoperative fine-needle aspiration biopsy of thyroid nodules in a community hospital. Archives of Surgery, v. 137, n. 7, p. 818–821, 2002.
COELI, C. M. et al. Incidência e mortalidade por câncer de tireóide no Brasil. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 49, n. 4, p. 503–509, 2005.
EGSET, A. V. et al. Risk of malignancy in fine-needle aspiration biopsy in patients with thyroid nodules. Danish Medical Journal, v. 64, n. 2, 2017.
ESZLINGER, M. et al. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews, v. 28, n. 3, p. 322–338, 2007.
FALLAHI, P. et al. Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules. Current Genomics, v. 15, n. 3, p. 171–177, 2014.
GOMES, E. M. DOS S. ET AL. Frequency of thyroid carcinoma and thyroid autoimmunity in first- degree relatives of patients with papillary thyroid carcinoma − A single center experience. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 55, n. 5, p. 326-330, 2011.
HIGASHIYAMA, M et al. Alpha‐1‐antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer, v. 76, n. 8, p. 1368-1376, 1995.
HUANG, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, v. 98, n. 26, p. 15044–15049, 2001.
INCA. Estimativa 2018. Incidencia de cáncer no Brasil. [s.l: s.n.].
INCA. Estimativa 2020. Incidência de Câncer no Brasil. [s.l: s.n.].
JARZA̧B, B. et al. Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Research, v. 65, n. 4, p. 1587–1597, 2005.
KATOH, H. et al. Classification and general considerations of thyroid Cancer. Annals of Clinical Pathology, v. 3, n. 1, p.1-9, 2015.
KURE, S.; WADA, R.; NAITO, Z. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma. Medical Molecular Morphology, v. 52, n. 4, p. 181-186, 2019.
LAI, M. L. et al. Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland. Histopathology, v. 33, n. 4, p. 332–336, 1998.
LAURSEN, I.; LYKKESFELDT, A. E. Purification and characterization of an α1-antichymotrypsin-like 66 kDa protein from the human breast cancer cell line, MCF-7. Biochimica et Biophysica Acta, v. 1121, n. 1–2, p. 119–129, 1992.
LAW, R. H. P. et al. An overview of the serpin superfamily. Genome Biology, v. 7, n. 5, p. 1-11, 2006.
LIN, J. DER; HSUEH, C.; HUANG, B. Y. Papillary thyroid carcinoma with different histological patterns. Chang Gung Medical Journal, v. 34, n. 1, p. 23–34, 2011.
MAROTTA, V. et al. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. Endocrine-Related Cancer, v. 23, n. 11, p. R499–R515, 2016.
NISHINO, N et al. The urokinase type of plasminogen activator in cancer of digestive tracts. Thrombosis research, v. 50, n. 4, p. 527-535, 1988.
OIKONOMOU, E. et al. BRAF vs RAS oncogenes: Are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget, v. 5, n. 23, 2015.
ORDÓÑEZ, N. G.; MANNING JR, J.T. Comparison of α-1-Antitrypsin and α-1-Antichymotrypsin in Hepatocellular Carcinoma: An Immunoperoxidase Study. American Journal of Gastroenterology, v. 79, n. 12, 1984.
PAN, D. H. et al. The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. OncoTargets and therapy, v. 10, p. 3261-3276, 2017.
PANEBIANCO, F. et al. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Medicine, v. 8, n. 13, p. 5831–5839, 2019.
PARK, J. H.; YOON, J. H. Lobectomy in patients with differentiated thyroid cancer: Indications and follow-up. Endocrine-Related Cancer, v. 26, n. 7, p. R381–R393, 2019.
PISHKARI, S. et al. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. Journal of Endocrinological Investigation, v. 41, n. 3, p. 269–283, 2018.
POBLETE, M.T. et al. Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. The American Journal of Surgical Pathology, v. 20, n. 3, p. 956-963, 1996.
QU, T. et al. Identification of potential biomarkers and drugs for papillary thyroid cancer based on gene expression profile analysis. Molecular Medicine Reports, v. 14, n. 6, p. 5041–5048, 2016.
RODRIGUES, H. G. C.; PONTES, A. A. N. DE; ADAN, L. F. F. Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocrine Journal, v. 59, n. 5, p. 417-424, 2012.
SADOWSKI, S. M.; TRIPONEZ, F. Diagnosis and management of indeterminate thyroid nodules. Gland Surgery, v. 8, n. Suppl 2, p. S60–S61, 2019.
TENG, H. et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics, v. 8, n. 16, p. 4345–4358, 2018.
UGURLUOGLU, C et al. Fine needle aspiration biopsy of thyroid nodules: cytologic and histopathologic correlation of 1096 patients. International Journal of Clinical and Experimental Pathology, v. 8, n. 11, p. 14800, 2015.
VAJARIA, B.N; PATEL, P.S. Glycosylation: a hallmark of cancer? Glycoconjugate Journal, v. 34, n. 2, p. 147–156, 2017.
VIERLINGER, K. et al. Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Medical Genomics, v. 4, n. 1, p. 30, 2011.
VUONG, H. G. et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. Clinical Endocrinology, v. 7, n. 5, p. 411-417, 2017.
WEBER, F. et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Journal of Clinical Endocrinology and Metabolism, v. 90, n. 5, p. 2512–2521, 2005.
XING, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews, v. 13, p. 184–199, 2013.
ZHANG, K. et al. Identification and validation of potential target genes in papillary thyroid cancer. European Journal of Pharmacology, v. 843, n. November 2018, p. 217-225, 2019.
Downloads
Publicado
2021-10-26
Como Citar
Santos, J. N., Queiroz, J. P. da S., Medeiros Neto, L. P., Santos, A. B. de O., & Canevari, R. de A. (2021). GENE SERPINA1: POTENCIAL MARCADOR DIAGNÓSTICO EM CARCINOMAS PAPILÍFEROS DA TIREOIDE. Revista Univap, 27(56). https://doi.org/10.18066/revistaunivap.v27i56.2578
Edição
Seção
Ciências da Saúde
Licença
Esse trabalho está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
Esta licença permite que outros distribuam, remixem, adaptem e criem a partir do seu trabalho, mesmo para fins comerciais, desde que lhe atribuam o devido crédito pela criação original.
http://creativecommons.org/licenses/by/4.0/legalcode
DOI:
https://doi.org/10.18066/revistaunivap.v27i56.2578Resumo
As neoplasias tireoidianas são o principal tipo de malignidade endócrina, sendo atualmente consideradas um problema de saúde pública com aumento constante em sua incidência nos últimos anos. A descoberta de marcadores moleculares que possam ser aplicados na rotina clínica em conjunto com a biópsia por aspiração com agulha fina (PAAF) pode propiciar um diagnóstico mais preciso e consequentemente um tratamento mais eficiente para o paciente. O objetivo desse estudo foi avaliar se o gene SERPINA1 pode ser considerado um marcador diagnóstico em carcinomas de tireoide. Foi realizada a análise de expressão gênica pela RT-qPCR, em 32 amostras de tecido tireoidiano, sendo 13 bócios, 11 carcinomas papilíferos, quatro carcinomas foliculares e quatro tecidos não tumorais de tireoide. A expressão aumentada do gene SERPINA1 foi observada nas amostras de carcinoma papilífero em comparação com amostras de bócio (P=0.0319) e com as amostras de carcinoma folicular (P=0.0430). Não foi observada expressão diferencial significativa entre amostras de carcinoma folicular com as amostras de bócio (P= 0.5329). Os resultados da análise de expressão gênica sugerem que o gene SERPINA1 pode ser considerado um marcador diagnóstico em carcinomas papilíferos de tireoide.Downloads
Referências
ABDULLAH, M et al. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. Peer Journal, v. 4, p. e2450, 2016.
BLANSFIELD, J. A.; SACK, M. J.; KUKORA, J. S. Recent experience with preoperative fine-needle aspiration biopsy of thyroid nodules in a community hospital. Archives of Surgery, v. 137, n. 7, p. 818–821, 2002.
COELI, C. M. et al. Incidência e mortalidade por câncer de tireóide no Brasil. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 49, n. 4, p. 503–509, 2005.
EGSET, A. V. et al. Risk of malignancy in fine-needle aspiration biopsy in patients with thyroid nodules. Danish Medical Journal, v. 64, n. 2, 2017.
ESZLINGER, M. et al. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews, v. 28, n. 3, p. 322–338, 2007.
FALLAHI, P. et al. Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules. Current Genomics, v. 15, n. 3, p. 171–177, 2014.
GOMES, E. M. DOS S. ET AL. Frequency of thyroid carcinoma and thyroid autoimmunity in first- degree relatives of patients with papillary thyroid carcinoma − A single center experience. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 55, n. 5, p. 326-330, 2011.
HIGASHIYAMA, M et al. Alpha‐1‐antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer, v. 76, n. 8, p. 1368-1376, 1995.
HUANG, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, v. 98, n. 26, p. 15044–15049, 2001.
INCA. Estimativa 2018. Incidencia de cáncer no Brasil. [s.l: s.n.].
INCA. Estimativa 2020. Incidência de Câncer no Brasil. [s.l: s.n.].
JARZA̧B, B. et al. Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Research, v. 65, n. 4, p. 1587–1597, 2005.
KATOH, H. et al. Classification and general considerations of thyroid Cancer. Annals of Clinical Pathology, v. 3, n. 1, p.1-9, 2015.
KURE, S.; WADA, R.; NAITO, Z. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma. Medical Molecular Morphology, v. 52, n. 4, p. 181-186, 2019.
LAI, M. L. et al. Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland. Histopathology, v. 33, n. 4, p. 332–336, 1998.
LAURSEN, I.; LYKKESFELDT, A. E. Purification and characterization of an α1-antichymotrypsin-like 66 kDa protein from the human breast cancer cell line, MCF-7. Biochimica et Biophysica Acta, v. 1121, n. 1–2, p. 119–129, 1992.
LAW, R. H. P. et al. An overview of the serpin superfamily. Genome Biology, v. 7, n. 5, p. 1-11, 2006.
LIN, J. DER; HSUEH, C.; HUANG, B. Y. Papillary thyroid carcinoma with different histological patterns. Chang Gung Medical Journal, v. 34, n. 1, p. 23–34, 2011.
MAROTTA, V. et al. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. Endocrine-Related Cancer, v. 23, n. 11, p. R499–R515, 2016.
NISHINO, N et al. The urokinase type of plasminogen activator in cancer of digestive tracts. Thrombosis research, v. 50, n. 4, p. 527-535, 1988.
OIKONOMOU, E. et al. BRAF vs RAS oncogenes: Are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget, v. 5, n. 23, 2015.
ORDÓÑEZ, N. G.; MANNING JR, J.T. Comparison of α-1-Antitrypsin and α-1-Antichymotrypsin in Hepatocellular Carcinoma: An Immunoperoxidase Study. American Journal of Gastroenterology, v. 79, n. 12, 1984.
PAN, D. H. et al. The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. OncoTargets and therapy, v. 10, p. 3261-3276, 2017.
PANEBIANCO, F. et al. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Medicine, v. 8, n. 13, p. 5831–5839, 2019.
PARK, J. H.; YOON, J. H. Lobectomy in patients with differentiated thyroid cancer: Indications and follow-up. Endocrine-Related Cancer, v. 26, n. 7, p. R381–R393, 2019.
PISHKARI, S. et al. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. Journal of Endocrinological Investigation, v. 41, n. 3, p. 269–283, 2018.
POBLETE, M.T. et al. Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. The American Journal of Surgical Pathology, v. 20, n. 3, p. 956-963, 1996.
QU, T. et al. Identification of potential biomarkers and drugs for papillary thyroid cancer based on gene expression profile analysis. Molecular Medicine Reports, v. 14, n. 6, p. 5041–5048, 2016.
RODRIGUES, H. G. C.; PONTES, A. A. N. DE; ADAN, L. F. F. Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocrine Journal, v. 59, n. 5, p. 417-424, 2012.
SADOWSKI, S. M.; TRIPONEZ, F. Diagnosis and management of indeterminate thyroid nodules. Gland Surgery, v. 8, n. Suppl 2, p. S60–S61, 2019.
TENG, H. et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics, v. 8, n. 16, p. 4345–4358, 2018.
UGURLUOGLU, C et al. Fine needle aspiration biopsy of thyroid nodules: cytologic and histopathologic correlation of 1096 patients. International Journal of Clinical and Experimental Pathology, v. 8, n. 11, p. 14800, 2015.
VAJARIA, B.N; PATEL, P.S. Glycosylation: a hallmark of cancer? Glycoconjugate Journal, v. 34, n. 2, p. 147–156, 2017.
VIERLINGER, K. et al. Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Medical Genomics, v. 4, n. 1, p. 30, 2011.
VUONG, H. G. et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. Clinical Endocrinology, v. 7, n. 5, p. 411-417, 2017.
WEBER, F. et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Journal of Clinical Endocrinology and Metabolism, v. 90, n. 5, p. 2512–2521, 2005.
XING, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews, v. 13, p. 184–199, 2013.
ZHANG, K. et al. Identification and validation of potential target genes in papillary thyroid cancer. European Journal of Pharmacology, v. 843, n. November 2018, p. 217-225, 2019.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Esse trabalho está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
Esta licença permite que outros distribuam, remixem, adaptem e criem a partir do seu trabalho, mesmo para fins comerciais, desde que lhe atribuam o devido crédito pela criação original.
http://creativecommons.org/licenses/by/4.0/legalcode
